![]() Selling, general & administrative expenses rose 63.1% to $13 million. The gross margin expanded 40 basis points (bps) to 79.1%. In the quarter under review, Surmodics’ gross profit (profit after excluding only Product costs of $5.1 million from total revenues) rose 4.8% to $19.7 million. Research, development and other revenues were $2.1 million, down 28.5% year over year. Royalties and license fees revenues totaled $8.8 million, flat year over year. In the quarter under review, Product sales were $13.9 million, up 15.2% from the prior-year quarter. ![]() The company reports consolidated revenues of its two segments under three categories - Product sales, Royalties and license fees, and Research, development and other fees. In the quarter under review, IVD sales improved 3% to $7.3 million on the back of strong product sales, partially offset by lower research & development revenues. The growth in revenues was driven by strong product sales. In the reported quarter, sales at the Medical Device segment were $17.5 million, up 5% from the year-ago quarter. Surmodics operates via two reportable segments - Medical Device and IVD. price-consensus-eps-surprise-chart | Surmodics, Inc. To read this article on click here.Surmodics, Inc. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. And, based on the above valuation metrics, we feel that EYE is likely the superior value option right now. These metrics, and several others, help EYE earn a Value grade of B, while SRDX has been given a Value grade of C.ĮYE is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. SRDX currently has a PEG ratio of 17.27.Īnother notable valuation metric for EYE is its P/B ratio of 4.58. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. We also note that EYE has a PEG ratio of 2.23. Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.ĮYE currently has a forward P/E ratio of 51.41, while SRDX has a forward P/E of 172.68. Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels. But this is just one piece of the puzzle for value investors. ![]() Investors should feel comfortable knowing that EYE likely has seen a stronger improvement to its earnings outlook than SRDX has recently. National Vision and SurModics are sporting Zacks Ranks of #2 (Buy) and #4 (Sell), respectively, right now. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Investors interested in Medical - Products stocks are likely familiar with National Vision (EYE) and SurModics (SRDX).
0 Comments
Leave a Reply. |